What to expect in the SELLAS Life Sciences Group, Inc. interview process

Based on publicly available sources and company profiles, SELLAS Life Sciences Group, Inc. is a micro-cap, late-stage clinical biopharmaceutical company headquartered in New York, NY (with a presence in Zug, Switzerland). Founded in 2006 (with an IPO in 2018), the company operates with an extremely lean organizational footprint, maintaining an employee headcount typically ranging between roughly 11 and 25 people (such as 13 employees reported recently).

The executive leadership team is led by President and Chief Operating Officer Angelos M. Stergiou, alongside Dragan Cicic (Chief Development Officer), John T. Burns (CFO), Andrew Elnatan (Regulatory Affairs, CMC, and Quality), and Stacy E. Yeung (General Counsel and Corporate Secretary). Its clinical pipeline focuses on cancer immunotherapies and treatments, prominently featuring product candidates such as galinpepimut-S (GPS) and SLS009 (GFH009), developed through licensing agreements with institutions like Memorial Sloan Kettering Cancer Center and GenFleet Therapeutics.

Because of its ultra-lean operational structure—operating more akin to a virtual or tightly-knit clinical-stage biotech rather than a large pharmaceutical corporation—prospective job seekers should expect a high-visibility, fast-paced environment where individual responsibilities span broad domains. Public data and search results do not provide granular day-to-day employee reviews, specific interview loops, internal office-return mandates, or exact cultural feedback, but candidates interviewing with SELLAS will interact directly with senior management due to the organization's small scale.